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Abstract
Earl Brewer discusses his journey into pediatric rheumatology from 1958 to retirement in 1990 in
three parts.
Part II: The PRCSG and the Park City meetings 
in the US
IV Pediatric Rheumatology Collaborative Study Group 
(PRSCG) – 1973
The beginning of the PRSCG was part of the evolving plan
for the future of pediatric rheumatology in the US. I was
impressed with the work of Maxwell Finland in Boston in
an earlier era when he cobbled together a group of clini-
cians to effectively study antibiotics. I knew that we had to
develop methods to study medicines for children with
arthritis in the US. We were trapped in a circular equation.
There were many drugs coming to market for adults with
arthritis. I believed that many of these new drugs were
non-specific for pain relief and would be used to help all
types of pain as well as inflammation. Studies were per-
formed in adults with arthritis. No studies were being per-
formed in children because there were thought to be too
few children with arthritis. Therefore the pharmaceutical
companies could not justify studies in children for eco-
nomic reasons. Therefore we had no approved drugs to
give arthritic children because the efficacy and safety were
not studied in children. It was interesting to me to learn
that aspirin was grandfathered in as an approved drug
when the US Federal Drug Administration (FDA) was first
created many years ago.
I had previously studied indomethocin and acetami-
nophen in a blinded study of acute control of high fever
in children. I conducted the study at the Ben Taub Hospi-
tal in Houston. It was published in Arthritis and Rheuma-
tism in 1968. The study was able to show that
indomethocin was superior to acetaminophen in control-
ling fever. This was a short usage study, but no adverse
reactions occurred in the short dosage regimen. This
study, however, did not address the problem of obtaining
approval for the use of indomethacin in children.
Dr. James Gleichart of Abbott Laboratories contacted me
concerning an anti-inflammatory drug and a possible
study. This was the first interest of a drug company in
studying arthritis drugs in children. He informed me that
they were two years from studies in adults or children.
Nothing came of the contact.
The beginning of the remarkable era of the PRCSG
occurred when Dr. Stanley Gottlieb of McNeil Laborato-
ries expressed interest in children's studies for a new drug,
tolmetin, a nonsteroidal anti-inflammatory agent. Ralph
Wedgwood, a pioneering pediatric immunologist and
rheumatologist at the University of Washington in Seattle,
and I met with Stan Gottlieb in San Francisco. Ralph
trained at the Children's Hospital in Boston several years
before I was there. We both had a great interest in children
with arthritis and knew each other.
Published: 21 June 2007
Pediatric Rheumatology 2007, 5:14 doi:10.1186/1546-0096-5-14
Received: 19 June 2007
Accepted: 21 June 2007
This article is available from: http://www.ped-rheum.com/content/5/1/14
© 2007 Brewer; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 12
(page number not for citation purposes)
Pediatric Rheumatology 2007, 5:14 http://www.ped-rheum.com/content/5/1/14The meeting was an amazing watershed. McNeill was pre-
pared to study tolmetin in children effectively. They
already were leaders in medicines for children with such
drugs as acetaminophen. They had moved into the new
field of NSAIDS and were receptive to helping children. I
believe that Dr. John Harter of the approval group at the
FDA also encouraged them to be in contact. Ralph, a
member of the Wedgwood China family in England, was
a bubbly, gregarious, outspoken Englishman and had
bolted for the colonies and trained in Boston. Ralph was
interested in helping with the effort to develop a way to
study these drugs but was not interested in doing the stud-
ies himself. We developed with Stan Gottlieb what
became Segment I, Segment II, and Segment III Tolmetin
studies.
After this pivotal meeting, our already collegial group
studying criteria entered into active plans to develop our
methodology for drug studies and formed what became
known as the Pediatric Rheumatology Collaborative
Study Group, the PRCSG. The first members were Earl
Brewer, chair, Houston; John Baum, Rochester; Virgil
Hanson, Los Angeles, Chester Fink, Dallas; Jerry Jacobs,
New York City; Joseph Levinson, Cincinnati; Jane
Schaller, Seattle. [Figure 1] We had spirited discussions on
many occasions regarding the structure of the open, dou-
ble-blinded, and follow-up studies. We developed the
forms and methodology of study with McNeil Laborato-
ries, Dr. John Harter of the FDA, and Dr. Stan Gottlieb.
I am moving ahead of the story here, but we later had a
terrible disappointment after finishing the first landmark
studies. All of our studies were omitted from McNeil's
massive Excerpta Medica publication of the major studies
of tolmetin done by Dr. John Ward of the University of
Utah and his cooperative adult group sponsored by the
NIH. Someone in the marketing department had talked to
someone on Wall Street who said that some of the ana-
lysts were concerned that a drug that was effective and safe
in children must be too weak for adults in comparison
with other drugs. I still have the letter from McNeil telling
me of their decision not to publish. I was really distressed.
Distressed can be spelled in several ways. Fortunately, the
FDA approved Tolmetin for usage in children later. We, of
course, published the work in the Journal of Pediatrics in
1977 [1]. The publication was a new experience for all of
us. A big question was not the data, but how should we
list names on the publication and in what order. My main
interest was in putting in place a collegial way of listing
the first author. Even though I had put the whole arrange-
ment together and was the coordinating center, I felt that
we should alternate who would be the first author. It was
not the brightest decision, but it solved a problem and
preserved our collegial spirit at the time.
Another landmark event occurred in 1976. Edward H.
Giannini, a graduate student at the University of Texas
School of Public Health, was also employed at the Meth-
odist Hospital and Baylor. He worked with the new NIH
CLINFO computer program that effectively became the
Internet. I employed Ed to help with our data. Of course,
the rest is history. He completed his Doctor of Public
Health in 1979, and became our fulltime senior scientist
of the PRCSG. Ed was and is gifted in data, epidemiology,
and statistics. He and I became instant and close friends.
He and his colleagues took PRCSG, which continues
today, to several new levels.
Philosophy of Segment I, II, AND III Drug 
Studies
It is useful to relate a little of the philosophy of our stud-
ies. For detailed descriptions of the design and methodol-
ogy, the reader is directed to Journal of Rheumatology 9:1,
1982. The purpose of our studies was to study anti-rheu-
matic and anti-inflammatory drugs for efficacy, safety,
and dosage already studied in adults. The NSAIDs and
SAARDs were studied identically. The only variables that
differed were duration of the studies and criteria for entry.
Our concept of study was to perform exploratory, open
label, short-term studies to establish whether the children
tolerated the medication and whether improvement was
sufficient to warrant more stringent, blinded studies. The
open label studies were followed by double-blinded com-
parison studies. We completed the study cycle with an
open label portion to give the children who did receive
the medication an opportunity to receive it and also to
have a nine to twelve month exposure to learn about con-
tinued efficacy and tolerance.
PRCSG Group 1975Figure 1
PRCSG Group 1975. From left Drs. Adamski [McNeil Lab], 
John Baum, Chester Fink, Earl Brewer, Virgil Hanson, Joseph 
Levinson, & Stanley Gottlieb [McNeil Lab]. Dr. Jane Schaller 
is not pictured.Page 2 of 12
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with first doses about 50% of maximum dose. Dosage was
increased to tolerance over a 2 to 4 week interval depend-
ing on the length of study. SAARD studies usually called
for a single dosage for 6 months with increased dosage
afterward if necessary. The medications were almost
always from the pharmaceutical companies. Some studies
were funded by the NIH and were prepared separately.
Detailed and standardized forms were used and monitor-
ing was performed. Dosages were in meter-squared calcu-
lations in the early studies and mg/kg in some studies.
Joint examination techniques were carefully studied and
the clinic directors all tested each other to be sure we
called joint changes in similar ways. However, fundamen-
tal to success was the recording of the change in joint func-
tion at later visits to establish improvement or worsening
of joint manifestations of swelling, tenderness, loss of
flexion or extension. The change in joint status was the
critical measurement. The same examiner judged each
visit. Thus the error factor of subjective judgment was nul-
lified because the same error would be constant. Another
strong feature was that experienced clinic directors made
all of the evaluations.
Segment II studies were designed to study efficacy and
safety. The model was to compare the study drug to aspi-
rin in a double-blinded manner. This meant a mechanism
was necessary to blind not only the patient and family but
also the clinic director caring for the patient. We did this
by sending coded meds to the director from our coordi-
nating center or the pharmaceutical company. Later, in a
SAARD study, a pharmacist at the participating center
filled the prescription with a coded prescription. Both
methods worked successfully for us. Monitoring was done
mainly by the pharmaceutical company monitors who
made frequent visits to the site. Detailed data was col-
lected and analyzed. The data analysis was the product of
Ed Giannini's genius. The interested reader can retrieve
many publications of our data analysis techniques. Ed
also was the key person in supervising data collection and
compliance.
From the beginning we insisted on collecting our own
data and analyzing it for publication. This concept led to
some memorable battles with individual drug companies.
They wanted to interpret our data for the FDA. We com-
promised by using our data for our publications, and they
analyzed the same data for their own purposes. The data
for FDA approval was our data as it turned out in later
studies. Our credibility and data became the gold stand-
ard for studies in children with arthritis.
Explosive growth of the PRCSG
The FDA section devoted to anti-rheumatic drugs under
the supervision of Dr. John Harter became a friend of chil-
dren with arthritis. John suggested to drug companies that
they should now study anti-rheumatic drugs in children
because it was fair and the right thing to do. He insisted
that approval of the drugs for adults where the financial
incentive was paramount required studies in children
also. The effect was immediate. McNeill had also received
favorable mention for their pioneering venture with us.
We suddenly had a host of companies asking for our serv-
ices to study drugs in children. Our good fortune was that
we had labored hard to develop a methodology to study
these new drugs that were being called NSAIDs. Initially
they were thought to be for arthritis alone, but it was
apparent to all of us involved that the application was uni-
versal for pain relief and anti-inflammatory effect.
We soon had contacts and offers from Eli Lilly, Parke-
Davis, Sandoz, Ciba-Geigy, SmithKline, and several other
companies. The effectiveness of NSAIDs for pain relief
and reduction of inflammation gave great impetus to drug
companies to bring to market these compounds quickly.
In the early days when the push was for arthritic use alone,
I became aware of the generic pain relief when nursing
staff asked for the samples of NSAIDs for personal relief of
menstrual cramps.
We quickly became the only game in town for children's
studies, and we labored to fulfill the demand for studies.
This enabled us to have a wider selection of medicines for
children with arthritis. We performed studies on tolmetin,
naproxen, fenoprofen, meclofanamate, pirprofen, pro-
quazone, ketoprofen, oxaprozin, ibuprofen, and others.
Some drugs did not pass muster after a Segment I study
because of either unpleasant side effects, poor efficacy or
the drug company felt they had done their duty to the
FDA. Other than aspirin and one or two other exceptions,
most of the NSAIDs studied had virtually the same effi-
cacy and toxicity.
Many new organizational concepts were necessary for our
group. We were literally the blind leading the blind. We
had no template to follow. We decided not to incorporate.
This meant that each center had to make a separate sub-
contract with a sponsoring drug company for local pay-
ment. We were the coordinating center in Houston and
the contracts were negotiated by us. It was impossible to
have a set amount for each test and each clinic charge. The
variations in laboratory charges in the USA were mind-
boggling. Price differences more than 800% in certain
tests were unbelievable to me but true. The solution was
to have charges paid to each institution rather than try for
uniformity of amounts paid. We did pay the same amount
to each investigator for a visit and the same amount forPage 3 of 12
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drug company contracted with a central laboratory with
all specimens sent to that lab by mail. We had problems
obtaining results in a timely manner from the lab. As a
cost containment device, it was not satisfactory. The
advantage was that we had comparable data with less
error factors because the same lab was doing the tests.
Jerry Jacobs at Columbia in New York City always had the
highest fees (everything in NYC was higher). Jerry was our
good cop/bad cop and harassed the monitors of the drug
companies with incredible complaints. Several companies
refused to deal with him and required me to be the inter-
mediary; however, Jerry may have complained the most,
but he always finished what he promised and always did
it well. Most of the time his complaints were absolutely
correct and helped make the PRCSG stronger and more
respected.
The coordinating center in Houston was crucial to the
projects. The other members were concerned that I would
be paid more money. There was no understanding of how
much work was required to conceive, organize, and super-
vise the studies. After I retired, the money to support coor-
dination was finally corrected. With the addition of Ed
Giannini's skills in study design, data collection and sta-
tistics we added considerable efficiency to our efforts,
which were quickly recognized nationally. Inferential and
descriptive analyses were applied to the data that were
acceptable and understandable to both clinicians and stat-
isticians. In the 1970s Jane Schaller and I became a part of
the Advisory Committee of the FDA Anti-inflammatory
Group. Children had a seat at the table. We participated in
the formulation of the study guidelines for NSAIDs.
The study of SAARDs (slower-acting anti-rheumatic
drugs) by the PRCSG came in the early 1980s. They
required modification of our basic Segments I, II, and III
studies but were essentially the same as the NSAID stud-
ies. This addition to our program came as a result of the
interest by the National Institutes of Health in the PRCSG
and our efforts to study drugs in children. This need coin-
cided with the NIH program of cooperation with the
USSR in medical studies during the cold war.
Two early hopes For PRCSG studies: In addition to the
main purpose to provide approved drugs for children with
arthritis, my hope was that our use of identical study
methods would allow comparisons of drugs in a realistic
manner. We were able to do this with a number of studies.
I also hoped that we could build a database of studied
aspirin patients and use them as historical controls. We
could thus study a drug without a blinded control. Alas,
the first two Segment II studies comparing tolmetin to
aspirin and fenoprofen to aspirin were not similar enough
to justify elimination of blinded studies.
Four observations:
1. Data entry and analyses were performed better by our
own data processing unit than by each drug company's IT
personnel. The firms were too busy with other studies to
process data and report in a timely manner.
2. Most of the firms entering the area of NSAID and
SAARD studies were usually inexperienced in this area.
Even more importantly, we had to reinvent the wheel with
each drug company. Each new company supervisor had to
present his/her ideas of how the forms should be done
and how the data should be treated. It was always a pains-
taking exercise to persuade them that we had our own
methods and data analysis. They always came to the same
view that the standardized, proven methods of our group
were better than reinventing the wheel, but it was always
difficult and time-consuming.
3. Even though FDA personnel were sympathetic to the
need of children for these medicines, FDA approval to use
these drugs in children proved to be an elusive and time-
consuming exercise. There were people who pushed for
safety and dosage testing only with no provisions for effi-
cacy testing. For a period of years there were shifting goal
posts for approval.
4. The expense to bring a drug to market was and is outra-
geous. About 40 million dollars were needed in the 1970s
and 1980s. Now in the 2000s, several hundred million
dollars are necessary. The patent law rules of a 17-year
window from patent to end of patent protection were
unreasonable in the old days and are still unreasonable. It
usually required seven to ten years or more to gain FDA
approval for a given drug. This resulted in a drug company
needing to charge enough to recover outlay expense in
only seven years. One can argue the problem in many
ways, but the result was and is outrageous prices for drugs.
The drug companies in recent years have not covered
themselves with honor and glory in pricing drugs differ-
ently in the rest of the world than here at home.
Reflections on the first nine years of the PRCSG
I published an editorial on our drug trials in the Journal
of Rheumatology in 1982, much of which has just been
discussed [2]. Additionally, our small collegial group was
working on the JRA criteria, striving for a place at the table
with adult rheumatologists, trying to be heard by the
American Academy of Pediatrics, and attempting to per-
suade the medical schools to include rheumatology in the
pediatric department curricula. Our task was daunting.
The FDA was a pleasant surprise. Dr. John Harter believed,Page 4 of 12
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drugs to help them. Our success was due in large part due
to this recognition. Our methodology was cutting-edge
and became a gold standard for anti-rheumatic drug stud-
ies in children.
A major concept that we fought to make an integral part
of studies was the double-blinded study of drugs. A few of
our small group felt that double-blinded, placebo studies
with allowance for a base NSAID were unethical. Jane
Schaller was the most concerned. When we planned our
first blinded SAARD study using gold, d-penicillamine,
and placebo, Jane objected. These concerns spread to Nor-
way when one of the highest officials of government held
special hearings on the ethics of the concept. We prevailed
thanks to an enormous effort by Dr. Hans Martin Hoyer-
aal of Oslo. Interestingly, it turned out that the children
who received the placebo were the safest because neither
penicillamine nor hydroxychloriquine were really effec-
tive. The children not on the drugs had no exposure to tox-
icity. At these times the placebo was the safest drug to use.
The FDA connection was in some ways a double-edged
sword. After a few years, it was apparent to several of us
that a large number of "me-too" drugs were coming to
market. The NSAIDs were remarkably similar in action
and toxicity. There were a few differences such as the sig-
nificant liver toxicity of aspirin as well as its ability to pro-
duce gastrointestinal bleeding. Most of the other NSAIDs
were markedly less with regard to these toxicities.
Indomethocin was a sleeper drug for toxicity and did
cause serious GI bleeding. The basic question was how
many NSAIDs should be studied. I initially thought that
we should not study so many of them. Two events
changed my mind. All children did not respond to a given
NSAID. Karyl Barron, Don Person, and I reviewed over a
hundred patients who received more than one NSAID and
79 had toxicity. About one-half of these children had tox-
icity to the second drug, and almost two-thirds had a sim-
ilar toxicity. We therefore needed more NSAID options for
children with arthritis. The second event was finding that
efficacy for one child is not necessarily the same for
another child. We had children who had marked
improvement on a certain NSAID and no improvement
on another. These selected differences were not apparent
in studies of children in a single study but were noted only
after a large number of the NSAID drug studies were com-
pleted.
The late 1970s were years of epiphany for our group. Sev-
eral important facets of our progress came into being or to
fruition at this time. The FDA included me in their Arthri-
tis Advisory Committee where I was chair of a subcommit-
tee to write guidelines for the study NSAIDs. The NIH
included us in the USA-USSR scientific cooperative stud-
ies. The future and fate of the PRCSG became totally
entwined with the NIH and the FDA from these years
onward. The NIH sponsored the adult group under Dr.
John Ward's Chairmanship to do cooperative studies in
adults with arthritis. John was Professor of Medicine at the
University of Utah and my friend. In fact, John, the FDA,
and the NIH wanted me to move to Salt Lake City where
the adult and pediatric study programs could be joined
and supported by the NIH. It almost came to fruition. My
wife Ria and I built a house in Park City, Utah in 1975 and
in 1977 I successfully took the Utah medical board by oral
exam. I was on the advisory committee of John's Cooper-
ative Studies Group. Ria's parents became seriously ill in
the late 1970s, and we decided to stay in Houston.
V NIH-USA-USSR scientific cooperation 
program 1975
An apparently unrelated pivotal event for pediatric rheu-
matology occurred on May 23, 1972. President Richard
Nixon and Secretary Leonid Breznev of the USSR signed
an agreement of scientific cooperation. The purpose was,
of course, to cooperate in areas that posed no threat to
either nation during the cold war. The thesis as presented
to me by Dr. John Decker of the NIH was that we would
either learn to work together or we would die together.
Children with arthritis turned out to be the major point
group for this concept. This event changed the course of
pediatric rheumatology and intertwined the PRCSG, pedi-
atric rheumatology, the FDA, and the NIH into a cooper-
ating functioning partnership that propelled our cause
into new levels of acceptance and effectiveness.
As I understand the story from several participants, Secre-
tary Weinberger of HHS was asked by President Nixon
what disease he would choose as the first thrust of the sci-
entific cooperation. Weinberger's wife had severe arthritis,
and he suggested it. Fortuitously, the USSR's strongest
medical specialty was rheumatology and had been since
the days of Stalin. Professor Nesterov was Stalin's physi-
cian. He was a rheumatologist also. Thus, compared to
other fields, rheumatology became a favored specialty for
funding over many years. Spin forward quite a number of
years to the1970s. Professor Valentina Nassonova was
Secretary of the Academy of Medical Sciences (AMS) of the
USSR (in the Soviet system the secretary was the leader of
a group or committee) as well as Chair of the Institute of
Rheumatology of the USSR. The AMS owned all of the
research institutes of the USSR and reported directly to the
Supreme Soviet (their Congress) rather than to the Minis-
try of Health.
The Russians wanted to study arthritis also -no surprise.
The first meeting was at the Stone House of the NIH in
May 1975. There were three Russians: Nassonova, Dr.
Margarita Ivanova, and Professor A. Speransky.Page 5 of 12
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2] [Figure 3] The members of both groups felt at ease with
each other and were honest with each other at all times.
Basically our Soviet counterparts were the same as our
group. They were interested in the welfare of children and
families and wanted to provide the best care for them. In
this way medicine has always been so universal with great
commonality of interest and personality the world over.
As individuals they were also interested in achieving as
much success as possible in the terms of their system.
Most were not very politically minded. In achieving our
mutually agreed goals for our studies, each of us carefully
discussed how we could work each of our systems to get
permission to do the studies to help the children and their
families.
The late Professor Dolgopolova was the original director
of Pediatric Rheumatology in the USSR. [Figure 4] She was
truly one of the great physicians of our time, and I still
miss her integrity, intelligence, humility, sense of humor,
and can-do, problem-solving abilities. She and Professor
Nassonova were two of the best problem-solvers I have
ever encountered. In my initial discussions with Professor
Dolgopolova in 1976, she stated that the results of our ini-
tial study of the epidemiology of JRA in the USSR-USA,
including a five-year follow-up of patients, must be pub-
lished in scientific journals of both countries. I explained
to her that in the United States, we would prepare the
paper to both our satisfactions and submit it to the editor
of an American journal who would review the paper for
approval as to quality. She then replied. "Da, it is the same
here in the USSR – Of course, I am also the editor." She
then asked about medical specialty training in the USA. I
explained that two to four years of training were custom-
ary and that the candidate had to pass an examination
given by a board to establish competence. She smiled and
said, "Da, it also the same here – Of course, I give the
board examination."
Our first study did not involve medicines for arthritis.
Rather it was a joint effort to establish that JRA was the
same entity in both countries and to ascertain the out-
come after five years or more in both countries. John
Baum of Rochester, Professor Dolgopolova, Lev Alexeev,
and I were responsible for the study. One center was used
in the USSR and five centers in the USA. Publication was
in Arthritis and Rheumatism in September 1980 [3] with
a companion publication in the comparable Russian jour-
nal. We established that JRA is the same in both countries
and that the long-term course of disease is about the same
in both countries.
The second study of two anti-rheumatic drugs, d-peni-
cillamine and hydroxychloroquine, tested against placebo
resulted in uncharted territory involving the Pharmaco-
logical Committee of the Ministry of Health, USSR. We
also had the need for substantial funding from the NIH as
well as permission to do the study from the FDA. There
was considerable discussion on our side about whether
we should give the Soviets our expertise in good drug
studies. There was also a disdain by certain factions at the
NIH who argued that the time and money were a waste of
the expertise of the NIH and should be paid for by the
State Department and not the highly sophisticated NIH.
With a great deal of pressure from John Decker and several
of his colleagues at the NIH, a contract was awarded to the
Pediatric Rheumatology Collaborative Study Group with
USA-USSR Signing agreements 1976 -MoscowFigure 3
USA-USSR Signing agreements 1976 -Moscow. From 
left: Professor Valentina Nassonova, USSR Academy OF 
Medical Science, and Dr. John Decker, USA-NIH signing 
Memorandum of Understanding 1976.
NIH USSR Visit 1976Figure 2
NIH USSR Visit 1976. From left: Drs. Charles Christian, 
Manuel Rudd, Ralph Williams, Lawrence Shulman, Israel Jaffe, 
2 Russian hosts, Alphonse Matulis, Russian host, John 
Decker, Morris Ziff, Fred Steinberg, Gerald Rodman, John 
Mill, Robert Swezey, John Baum, Lev Alexeev. Earl Brewer 
took picture.Page 6 of 12
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only for the USA side, however, and certain powerful peo-
ple in the NIH instructed me directly and indirectly to not
even mention the USSR side of the study. At the end of the
study, I simply ignored the orders and wrote a report with
Dr. Giannini and group, published in the New England
Journal of Medicine (NEJM) in May 1986 [4]. It was pre-
sented as the number one paper at the American Rheuma-
tism Association (ARA) Meeting in Los Angeles in 1985.
The study took 8 years from first planning to publication.
A total of 162 USA-USSR children participated in the one-
year study. This marked the first time that the Soviets
requested permission from the NEJM to publish essen-
tially the same paper in a Russian journal Rheumatology.
Even more intrigue occurred in obtaining permission to
do a study of auranofin (oral gold) and placebo in chil-
dren with JRA (231 USA-USSR children) combining the
efforts of a pharmaceutical company, the NIH, and the
Soviets. The last event was to do a study of methotrexate
and placebo in children with JRA combining the PRCSG,
the FDA, the NIH, a pharmaceutical company, and our
colleagues in the USSR. The FDA had not worked with the
USSR before, and with reason, many people were worried.
To everyone's credit the problem was solved with only
two PH (pigeon hole) syndrome expeditions at the FDA
necessary.
Our Soviet counterparts had even more trouble. The head
of the Pharmacological Committee of the USSR (the Rus-
sian equivalent of the FDA) went head to head with Pro-
fessor Nassonova of the Academy of Medical Sciences over
turf. He maintained with justification that any blinded,
research drugs should come under his supervision. Nas-
sonova maintained that the Academy of Medical Sciences
of the USSR had made agreements with the National Insti-
tutes of Health of the USA directly, and the subject matter
was none of his concern. The control problem continued
through our last three studies. The crux of the argument
was that the USSR Ministry of Health and Pharmacologi-
cal Committee wanted to go into the drug study business.
They could bid about one-third of the usual cost in the
USA for a comparable study. The problem was that no one
was buying. They needed credibility. Hence, the turf war
resulted. Nassonova and I pointed out to them that under
the terms of the bilateral agreements each must bear the
cost of a study in its own country. Therefore it was impos-
sible for the USA to pay for the expenses of the studies in
the USSR.
We dealt with three different officials of the Ministry of
Health for each study. Professor Lepachin of the Pharma-
cological Committee stymied the first drug study of d-
penicillamine and hydroxychloroquine. Lepachin had
impounded the study drugs at the airport. It was solved on
this occasion when Nassonova and I liberated the study
drug at the airport in Moscow. It was a great lesson in
gutsy diplomacy watching Nassonova stare down the Cus-
toms Director at Sheremeteva Airport.
The second study of drugs was auranofin and placebo.
This time, Professor Babayan, an Armenian at the Ministry
of Health, impounded the drug by taking them to his
office at the Ministry to be sure that we did not liberate
them again. Nassonova, Kuzmina, Shaikov, Alexeev, and
I met with him on a cold December day in Moscow in
1984. After much discussion he agreed to let the study
1978 – Moscow – Russian colleagues and Giannini – Insitiute of rheumatol gyFigure 5
1978 – Moscow – Russian colleagues and Giannini – 
Insitiute of rheumatology. Standing from left: Drs. Boris 
Shokh & Alexandr Shaikov. Sitting from left: Dr. Margarite 
Ivanova, Dr. Earl Brewer, Professor Nina Kuzmina, Dr. A. 
Yakovleva, Dr. Nina Melikova, and Dr. Edward Giannini.
1976 USA-USSR Pediatric rheumatology meeting – MoscowFigure 4
1976 USA-USSR Pediatric rheumatology meeting – 
Moscow. Front row from left: Dr. John Baum and Professor 
Alexandra Dolgopolova. Back row from left: Dr. Earl Brewer, 
Dr. Andrew Kang, Professor Alexandra Isaeva, Professor 
Nina Kuzmina, and Dr. Alexandr Shaikov.Page 7 of 12
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be released until the SmithKline Pharmaceutical paid a
registration fee. We did the study and it was reported in
both the USA and USSR in 1988. We still have not been
told how to register the drug.
Professor Pokryshkin replaced Babayan, and in July 1987,
Nassonova, Shaikov, Kuzmina, and I went head to head
with Pokryshkin. He placed us around the conference
table with me on one side and all the Russians on the
other side. They spoke Russian for about one half hour
with a lot of nodding and pointing. Nassonova early on
pointed to Shaikov and said, "Alexandr, Professor Brewer
is over there by himself. Sit with him and translate."
Finally Pokryshkin suddenly smiled and said in perfect
English. "Ah, Professor Brewer. I finally understand the
problem." Nassonova smiled and said, "Professor Pokry-
shkin had forgotten that it is unethical for us in the USSR
to accept money for the study of drugs to help our chil-
dren. It is quite impossible."
Thus the study of methotrexate was tentatively approved.
However, Professor Lepachin was not through with us yet.
Professor Pokryshkin was reassigned with a new reorgan-
ization at the Ministry of Health. Professor Lepachin, who
had been my friendly adversary for those many years,
remained the Chairman of the Pharmacological Commit-
tee. We have never met to this day. His next and last move
was to convene a meeting of his committee and ask sev-
eral very pertinent questions about the drug. Dr. John
Harter and Dr. Kent Johnson of the FDA, Dr. Jack Klippel
of the NIH, Dr. Margaret Gandt of Lederle Laboratories,
Dr. Giannini, and myself addressed these issues with an
appropriate letter sent by Dr. Marlene Haffner, Director of
the FDA's Orphan Products Division. Finally on January
13, 1989, the study of methotrexate in the USSR was
approved and the medication was shipped without event
and the study and was completed October 1, 1990 and
published in the New England Journal of Medicine in
1992. In an article published in the British periodical,
Nature, March 19, 1987, Dr. James Wyngaarden, Director
of the National Institutes of Health, stated that the meth-
ods developed by the USA-USSR pediatric rheumatology
scientific cooperative group had pointed the way for the
expanding NIH research efforts with the USSR.
The Giannini years with the PRCSG – 1976
I don't remember the first time that we met, but Ed was
completing his doctorate of public health at the Univer-
sity of Texas School of Public Health. He came to work for
me part-time to help with our data. Ed was a larger-than-
life, effervescent, assertive, happy Italian-American who
burst into a room and took over. He brought enthusiasm,
efficiency, and competence to our efforts. At that time he
was single and also our Casanova-in-residence. We lived
vicariously through Ed's adventures. His knowledge of
computers and data filled a void and allowed the PRCSG
to blossom, and blossom it did. Over the next decade or
so we studied 15 or more drugs in various segmental stud-
ies.
The PRCSG had reached a turning point when Ed joined.
We moved to the next level of organization of our colle-
gial group of eight members (Brewer, Baum, Cassidy,
Fink, Hanson, Jacobs, Levinson, and Schaller). We
embedded Segments I, II, and III methodologies into a
codified, written system. All studies started and ended
with the standardized methodology. We also wrote and
approved by-laws and rules and regulations whereby the
chair was elected along with a few center directors. Later
we added members from the FDA and the NIH. The sys-
tem worked well with a few bumps along the way. We
established our credibility with our peers, the then-ARA,
the FDA, the NIH, the drug industry, and the AAP.
Ed quickly became essential as our senior scientist. He was
our coordinating operating officer for data and custom-
ized software to fit our needs for data processing and form
development. [Figure 5] The PRCSG held frequent meet-
ings, usually before and after different studies. We ham-
mered firm and standardized methods of examining
patients, how to pay each center, and data processing. We
held firm to our agreed methods when several agencies or
people tried to change our mission. We published our
concepts and methodology in a number of journals and
books.
In the middle or late 70s, I came to the mistaken conclu-
sion from organizational data supplied by allegedly
learned people that no more than six clinics could do
joint studies together efficiently. We were in the process of
approving several of the fifteen studies that we performed,
and I thought that adding a Group II would double our
capacity for studies. We asked Jack Bass of Ohio State
Medical School in Columbus to be chair. Other members
were Balu Athreya at Children's Hospital of Philadelphia,
Donald Goldsmith at Temple in Philadelphia, J. Roger
Hollister at the Jewish Hospital in Denver, Deborah
Kredich at Duke in Durham, North Carolina, John J.
Miller at Stanford Medical School in Palo Alto, and Lauren
Pachman and Ken Rich at Northwestern Medical School
in Chicago. Previously we decided to add colleagues at
several of the original centers to help with the studies.
They were Harry Gewanter in Rochester, NY, Bram Bern-
stein in Los Angeles, Donita Sullivan in Ann Arbor, Mich-
igan, Norma Battles in Dallas, and William Crowe in
Cincinnati. The arrangement was short-lived. Group II did
one or two studies before it became apparent that the plan
did not work. Instead of promoting efficiency, we added a
layer of bureaucracy that hindered our mission instead ofPage 8 of 12
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separate entity, which would function independently of
the PRCSG board. We abandoned this concept in a few
years.
Our participation in CLINFO began in the late 70s or early
80s. This was the precursor of the Internet developed by
the Defense Department first and then the NIH to connect
research centers together by computer to facilitate inter-
change of data and ideas. Ed became a part of this project
while working at Methodist Hospital during his student
days. He included the PRCSG in the program. They even
ran an underground cable to our offices to connect us. In
a few years Ed was selected to help write the programs to
adapt CLINFO mainframes to the personal computer. We
were in the mainstream of progress in data research and
processing.
Ed and I fought many battles with a variety of interested
groups concerning study methodology. One faction felt
that children were little adults, and dosages could be
extrapolated with no concern for the problems of growth
and changes in a developing body. The cost of adding
children to adult studies was the driving force. The market
for children was small for the rheumatic drugs, but it
became clear to many of us that NSAIDs were going to be
needed for pain and anti-inflammatory effect in many
childhood conditions.
I have discussed the problem of placebo studies earlier. Ed
developed data treatments that were on the cutting edge
for our group of studies. He was clearly the glue that
bound the core of the PRCSG. When I retired in 1990, I
asked the group to continue Ed as Senior Scientist and
Dan Lovell as the Chair of the PRCSG with headquarters
at the University of Cincinnati. The board and member-
ship agreed and elected both. The PRCSG has moved to
new levels of sophistication far beyond our original begin-
nings with more than seventy centers now in the USA, a
European cooperating component, PRINTO, and fifteen
pediatric rheumatology centers in China led by Dr. He
Xiaohu in Beijing that may become a part of the group.
VI Pediatric Rheumatology Council on Pediatric 
Rheumatology – ARA-1976; Park City pediatric 
rheumatology meeting – 1976 – Park City I
Laurence Schulman and Gerald Rodnan, both presidents
of the ARA, appointed the first Pediatric Rheumatology
Council in 1976. The initial members were John Baum,
James Cassidy, Chester Fink, Virgil Hanson, Jerry Jacobs,
Joseph Levinson, Jane Schaller, Sydney Stillman, and
myself. The idea for the first PC meeting came from this
group, and the members became the program committee
for the meeting. The council was the natural outgrowth of
the JRA Subcommittee.
The Park City meeting from March 21-25, 1976 was
another pivotal breakthrough for our subspecialty in the
US and worldwide. Parallel events were moving so rapidly
that one has to place this seminal meeting in perspective
with the other rapidly moving events. The PRCSG was
hurtling forward in its destiny. We were just beginning our
studies with the Russians. The ARA recognized pediatrics
by forming a council on pediatric rheumatology. The JRA
criteria validation was on the road to being published in
1977.
I think that the original thrust probably came from the
ARA council meeting. Virgil Hanson and Jane Schaller
were co-chairs. Ria and I were building a house in the
then-undiscovered Park City ski resort town in Utah. We
met at Marsac Lodge at the Park City Ski Resort the first
time and later meetings were at our new house. In addi-
tion to Jane Schaller and Virgil Hanson, initial members
of the committee were John Baum, James Cassidy, Chester
Fink, Jerry Jacobs, Joseph Levinson, Sydney Stillman, and
myself. We obtained seed money from the Shriner's of
North America and the Lazarus Foundation. This was
essential early seed money. Larry Shulman of the NIH also
helped.
We had a number of committee meetings. Jane was
selected to be editor of the papers presented. Barbara
Ansell and Eric Bywaters of London were prominent par-
ticipants in absentia. Egos and alter egos were prominent.
Our collegial spirit prevailed. Sydney Stillman was a
strong guiding factor. Syd had no interest in skiing or any-
thing resembling it. We met in the Steeps room at the Park
City resort. Each morning Syd was early to rise for a brisk
walk in his tweed coat, white shirt, tie, slacks, and formal
Boston hat. His fellow walkers were headed to the gon-
dola in ski attire. He was wonderful. He had a cheery hello
for everyone he met.
Arthritis and Rheumatism agreed to publish the papers of
the meeting [5]. There had been nothing like it before. We
selected the Treasure Mountain Inn, a charming, old min-
ing inn on historic Main Street for +the meeting place. The
meeting room had a large fireplace with 1890s furniture
(Park City was a 1890s mining town), and easily held the
fifty-eight or so participants invited to the meeting. We ate
our meals at the Car 19 restaurant across the street. We
held our final banquet in the basement rock room of the
Car 19.
Everyone felt the excitement of the meeting. We knew that
this was a major breakthrough. We agreed to have several
series of patients with data at the beginning. The program
was truly a compendium of knowledge relating to pediat-
ric rheumatology. Three series were presented. Clinical
aspects of JRA including heart, joints, epidemiology,Page 9 of 12
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The other rheumatic diseases were also covered. Treat-
ment and family and patient education received promi-
nent roles. It was amazing to me to look at the breadth of
information. The Arthritis and Rheumatism publication
of the meeting in a Supplement in 1977 served as a refer-
ence of pediatric rheumatology for the next generation
[5].
A major highlight of the meeting for me was the wide-
angle color picture of all fifty-nine of us on the balcony of
the Treasure Mountain Inn taken at the end of the meet-
ing. [Figure 6] Jim and I resurrected it for subsequent
meetings. It is a classic picture of some of the pioneers in
our field.
Professor Eric Bywaters from London and Taplow was cer-
tainly our most distinguished and honored guest. He had
a remarkable ability to make everyone he met feel at ease.
The sly smile, his horn-rimmed glasses, and a slight duck-
ing of his head when making a point made his charisma
even more potent. He was slight of build with thinning
hair. Eric gave our main, after-banquet talk at the Car 19
restaurant on Main Street in Park City. His discussion of
the early observers of children with arthritis was clear and
wonderful. Eric, ever the gentle consensus builder, gave
his take on the initial pioneers who made pediatric rheu-
matology an entity. His comments are classic and are
recorded here:
"I think I saw it arrive, although I cannot specify its birth-
day or place and I am damned if I can read the father's sig-
nature on the birth certificate. We are very fortunately a
small enough group to know each other personally and to
cooperate and enjoy each other's company."
PARK CITY II – 1986
Many events moved in concert acted to create a golden era
for our cause. Park City II occurred ten years after the his-
toric Park City I, and a comparison showed how far pedi-
atric rheumatology had progressed. The meeting was held
March 15-19, 1986 in Park City, Utah and sponsored by
the Pediatric sections of the AAP and ARA, the AJAO of the
AF. The committee members were Balu Athryea, Earl
Brewer, James Cassidy, Virgil Hanson, and Bernard Sing-
sen. Three of the five members were members of the first
PC-I committee (Brewer, Cassidy, and Hanson). James
Cassidy and I were co-chairs. There were 17 invited papers
and 56 peer reviewed abstracts. Three distinguished, retir-
ing or retired pediatric rheumatologists were honored at
the meeting – J. Sydney Stillman, Joseph Levinson, and
Virgil Hanson. Each gave memorable talks at the meeting.
Syd gave his thoughts on the beginnings of pediatric rheu-
matology to the 1930s, when small groups at the Royal
Park City III 1991Figure 7
Park City III 1991. Dr. Earl Brewer [L] and DR. Barbara 
Ansell [R].
Park City I meeting 1976Figure 6
Park City I meeting 1976. Fifty-nine participants pictured 
at Treasure Mountain Inn, Park City Utah, 1976.Page 10 of 12
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matic diseases. He left this history to others and focused
on our American efforts.
"Thirteen physicians including two Nobel Laureates in
1932 held the first meeting of the American Committee
for the Control of Rheumatism. In five years, it became
the American Rheumatism Association (ARA). I first
attended the seventh meeting of the ARA in June 1940.
Only five papers were presented. Three (60%) of the
papers were devoted to children with rheumatic disease.
One of the papers was by Dr. William Green of the Chil-
dren's Hospital in Boston, His subject, "Monoarticular
and Pauciarticular Arthritis in Children."
Rheumatic fever was a major cause of rheumatic disease in
the first half of the twentieth century. The House of Good
Samaritan at the CHMC at Harvard treated rheumatic
fever for over 40 years from the 1920s to 1960s. In 1921
the first 100 cases, admitted with their first attack, had a
five-year mortality of 24 percent. By the 1950s the mortal-
ity was only 3 percent. Many reasons were given for the
decline: decrease in virulence and epidemicity of the
infecting strains of Group A streptococci, improvement of
living conditions, and most importantly, the advent of
penicillin. By 1960 the House of Good Sam as it was
called was closed for lack of patients. Syd reviewed the
important events propelling pediatric rheumatology for-
ward. His parting words and advice were profound and
useful to everyone. "I should like to think of the field of
rheumatology as it was when I entered it. It was an associ-
ation formed for the mutual aid and protection of its
members, and for the furtherance of some common pur-
pose. The guild was small enough that one knew most of
the members, both here and abroad. There was coopera-
tion in planning meetings, arranging for training fellows,
and sharing information. When one of your patients was
traveling, you knew you could refer him or her to a good
physician almost anywhere. Now that I have retired, I find
the warm relationships built up during my active years
still persist. I can give you no better advice than to be a
good, participating, generous member of the guild as we
work together toward a solution of the difficult problems
presented by the rheumatic diseases."
Joe Levinson's reflections and perspectives were equally
profound to me. He said that looking back over thirty
years, we had few tools in our armentarium – only a few
drugs, few helpful surgical interventions, unproven and
controversial physical programs, but a lot of faith. We also
had a great deal of clinical curiosity, so we systemically
studied the children we treated. We sought to describe and
classify disease. We tried to visualize the relationships of
spectrum of disease and comprehend relation to varied
responses to common exposures. We searched for under-
standing of both technical and emotional roles we played
in the lives of children. Classification was only a starting
point for predicting functional outcomes for individuals
because coping strategies, expectations of the families,
and perceptions of the disease and child by schools and
other community agencies were just as important. We had
to develop teams as part of the patient's extended family
to develop realistic expectation of performance.
The progress in 10 years was breath taking to those of us
who were there from the beginning. Fifty-eight profes-
sionals participated in Park City I in 1976. Two hundred
professionals attended Park City II. In 1976 there were 17
pediatric rheumatology clinics and 22 pediatric rheuma-
tologists in the USA and 4 clinics and 13 pediatric rheu-
matologists Canada. Ten years later the number of clinics
increased to 71 and pediatric rheumatologists to 103. In
Canada the numbers increased to eight clinics and 13
pediatric rheumatologists. Nine peer reviewed pediatric
rheumatology papers were accepted for presentation at
the ARA meeting in 1975. In 1985 the number accepted
increased to 35.
Other Major Conferences: The EULAR Conference in 1977 
in Oslo
This conference was a pivotal event that firmly established
our USA connection with our colleagues in Europe and
revealed the deeply felt differences of approach, treat-
ment, and classification. Eimar Munthe of Oslo was our
host, and the symbol of the meeting was the crying child
sculpture by Viegland. It was here that Barbara Ansell, a
loved and revered legend of pediatric rheumatology, [Fig-
ure 7] and colleagues passionately pushed their feelings
about classification. Essentially they wanted to rename
JRA, Juvenile Chronic Arthritis and wanted to do it by
executive decision and not by detailed studies. We felt that
too much effort had been expended in validating our
American ARA studies to change. Also Ansell and Phillip
Wood wanted to add ankylosing spondylitis, psoriatic
arthritis, and later enthesitis.
There were two major forces at work. Barbara wanted to
pursue her goals for development of pediatric rheumatol-
ogy through EULAR in Europe. She did not want the
PRCSG to form a third unit in Europe. I tried to add Hoy-
eraal in Oslo, Anna Lisa Makeli in Finland, and others in
Europe to our American PRCSG group. The correspond-
ence in the papers in my archives is fascinating. Phillip
Wood and Barbara Ansell suggested that the pediatric
rheumatologists in Europe who had signed up for the
PRCSG withdraw and asked the PRCSG to work exclu-
sively through the EULAR organization. In my opinion,
this move may have delayed cooperative drug studies in
Europe until the Pediatric Rheumatology International
Trial Organization's (PRINTO) birth years later.Page 11 of 12
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The Eightieth Ross Conference on Pediatric Research in 
1979
This meeting was a project led by Chester Fink. Chet had
several laudable agendas that he wished to promote. The
first agenda was to persuade Ross Laboratories to sponsor
the next Park City pediatric rheumatology meeting. The
Ross Conferences were highly prestigious in the pediatric
world at that time. This sponsorship would give us access
to over 30,000 pediatricians for educational purposes to
promote better understanding of children with arthritis.
His next agenda was to get the Park City meetings away
from the snow. He and other members of our small colle-
gial group had no interest in skiing or cold weather. We
therefore held the Ross meeting in the Bahamas at the
Xanadu Hotel, formerly the headquarters of Howard
Hughes. The quality of the meeting was a great success
and the publication of the meeting served as another pedi-
atric rheumatology reference. Unfortunately, the accom-
modations were not the best. While Cathy Hanson was
drawing a bath, the hot water faucet stuck in the on posi-
tion. Water ran over the side of the tub, into the room, and
into the hall. She was forced to get help with few garments
on her body. The stories went on and on. We returned to
Park City in1986 for Park City II.
Conclusion
The 1970's and early 1980's were an exciting time for
pediatric rheumatology both in the US and throughout
the world. The growth of our subspecialty from a few to
many was spectacular and our collaborative efforts in clas-
sification, meetings, drug studies both in the US and
abroad, and organization of our field were no less impres-
sive. I was delighted to have some role in these endeavors
and am happy to be able to describe these historical, pio-
neering steps in this three-part article. Soon-to-be-pub-
lished Part III will relate our early efforts to receive
support for pediatric rheumatology from the US govern-
ment, develop a section in the American Academy of Pedi-
atrics, begin a board certification process, and train
fellows to carry on our important work.
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